Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2018

01-06-2018 | Endocrine Tumors

Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma

Authors: Jong-kyu Kim, MD, Chan Yong Seong, MD, In Eui Bae, MD, Jin Wook Yi, MD, Hyeong Won Yu, MD, Su-jin Kim, MD, PhD, Jae-Kyung Won, MD, PhD, Young Jun Chai, MD, June Young Choi, MD, Kyu Eun Lee, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2018

Login to get access

Abstract

Background

BRAFV600E mutation is the most common somatic variant in papillary thyroid carcinoma (PTC) and is associated with aggressive prognostic factors. The conventional detection method for BRAF mutations is polymerase chain reaction followed by Sanger sequencing. Recently, an immunohistochemistry (IHC) method using a BRAFV600E-specific antibody (VE1) has been developed and widely adopted in the clinics; however, there is a lack of evidence regarding the comparability of the IHC and Sanger sequencing methods.

Methods

Our institution began using the BRAFV600E IHC test in January 2013. We retrospectively analyzed 697 samples that were tested using both the IHC and sequencing methods, and evaluated their concordance.

Results

BRAF mutation was detected in 90.0% (627/697) of samples using IHC and 83.4% (581/697) of samples using direct sequencing. The diagnostic parameters of IHC compared with Sanger sequencing were as follows: 100% sensitivity (581/581), 60.3% specificity (70/116), 92.7% positive predictive value (581/627), and 100% negative predictive value (70/70). No false negative results were recorded using IHC. The overall concordance rate between the two methods was 93.4% (651/697). Discordant results were found in 46 samples (6.6%), 29 of which were from cases with small tumors (< 6 mm), 8 were from cases with low tumor cellularity, and 9 were specimens yielding low-quality DNA.

Conclusions

IHC using the VE1 antibody is a reliable and highly sensitive method for detecting the BRAFV600E mutation in classic PTC.
Literature
1.
Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015;262:519–25.CrossRefPubMedPubMedCentral
2.
3.
Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010;200:136–43.CrossRefPubMed
4.
Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.CrossRefPubMed
5.
Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.CrossRefPubMed
6.
Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMed
7.
Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818–21.CrossRefPubMed
8.
Ihle MA, Fassunke J, Konig K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14:13.CrossRefPubMedPubMedCentral
9.
Kim BH, Kim IJ, Lee BJ, et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med J. 2015;56:634–40.CrossRefPubMedPubMedCentral
10.
Zagzag J, Pollack A, Dultz L, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery. 2013;154:1199–204.CrossRefPubMedPubMedCentral
11.
Wobker SE, Kim LT, Hackman TG, Dodd LG. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma. Cancer Cytopathol. 2015;123:531–9.CrossRefPubMed
12.
Zhu X, Luo Y, Bai Q, et al. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Exp Mol Pathol. 2016;100:236–41.CrossRefPubMed
13.
Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310–7.CrossRefPubMed
14.
Boursault L, Haddad V, Vergier B, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS ONE 2013;8:e70826.CrossRefPubMedPubMedCentral
15.
Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin N Am. 2009;23:529–45.CrossRefPubMed
16.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;27:949–54.CrossRef
17.
Mathur A, Moses W, Rahbari R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer. 2011;117:4390–5.CrossRefPubMedPubMedCentral
18.
Jung CK, Im SY, Kang YJ, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22:791–7.CrossRefPubMed
19.
Lee SE, Hwang TS, Choi YL, et al. BRAF Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAFV600E mutation. Thyroid. 2017;27:802–10.CrossRefPubMed
20.
Menzies AM, Lum T, Wilmott JS, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol. 2014;38:377–82.CrossRefPubMed
21.
Walts AE, Pao A, Sacks W, Bose S. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. Hum Pathol. 2014;45:935–41.CrossRefPubMed
22.
Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61–5.CrossRefPubMed
23.
Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15:94–100.CrossRefPubMed
24.
Zhang H, Zheng X, Ji T, et al. Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras Kit and Sanger DNA sequencing. Cell Biochem Biophys. 2012;62:415–20.CrossRefPubMed
25.
Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;23:1058–69.CrossRef
26.
McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci USA. 2014;111:1600–9.CrossRef
27.
Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718–26.CrossRefPubMedPubMedCentral
28.
Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118:1764–73.CrossRefPubMed
29.
Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine. 2012;91:274–86.CrossRefPubMed
30.
Xing M. BRAF mutation in papillary thyroid cancer: pathologenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–62.CrossRefPubMed
31.
Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501.CrossRefPubMedPubMedCentral
Metadata
Title
Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma
Authors
Jong-kyu Kim, MD
Chan Yong Seong, MD
In Eui Bae, MD
Jin Wook Yi, MD
Hyeong Won Yu, MD
Su-jin Kim, MD, PhD
Jae-Kyung Won, MD, PhD
Young Jun Chai, MD
June Young Choi, MD
Kyu Eun Lee, MD, PhD
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6460-3

Other articles of this Issue 6/2018

Annals of Surgical Oncology 6/2018 Go to the issue

Bone and Soft Tissue Sarcomas

Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard?

Pancreatic Tumors

Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center

Colorectal Cancer

Analysis of the Vascular Interrelationships Among the First Jejunal Vein, the Superior Mesenteric Artery, and the Middle Colic Artery

Melanomas

SPECT/CT Adds Distinct Lymph Node Basins and Influences Radiologic Findings and Surgical Approach for Sentinel Lymph Node Biopsy in Head and Neck Melanoma

Urologic Oncology

The Patient-Reported Information Multidimensional Exploration (PRIME) Framework for Investigating Emotions and Other Factors of Prostate Cancer Patients with Low Intermediate Risk Based on Online Cancer Support Group Discussions

Hepatobiliary Tumors

Progression of Colorectal Cancer Liver Metastasis After Chemotherapy: A New Test of Time?